Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it will present new clinical data and attend several renowned international conferences in June and July, all to be held virtually.
Dr. Carlos Buesa, Oryzon's CEO, will attend and present a corporate update at the "Emerging Biotech Company Showcase" hosted by NewYorkBIO and the New York Stock Exchange (NYSE), which will be held on June 23. The Showcase brings together New York's financial community and a group of emerging biotech companies that are developing novel therapeutics and technologies that could revolutionize patient care.
Dr. Buesa will also attend the Spring European Virtual MidCap Event, which will take place on June 24-25, where he will hold 1x1 meetings with international investors and pharma industry professionals.
The company will present initial, preliminary data of vafidemstat's ability to reduce the inflammatory response in COVID-19 patients from the ongoing Phase II trial ESCAPE at the 31st European Congress of Clinical Microbiology and Infectious Diseases, ECCMID-2021, which will be held on July 9-12. This clinical update will be presented in an e-poster entitled "ESCAPE trial: Preliminary data on the effect of vafidemstat treatment in the COVID-19 induced immune response in hospitalized patients", available through the on-demand virtual congress platform as of July 9. ESCAPE is an open-label, randomized, double arm Phase II trial to assess the efficacy and tolerability of vafidemstat in combination with standard of care, to prevent progression of severely ill COVID-19 patients with pneumonia to Acute Respiratory Distress Syndrome (ARDS), one of the main causes of death in this disease, by reducing the patient's inflammatory response to the infection. In accordance with the embargo terms and conditions for presentation at ECCMID-2021, data will be released on the same day as the communication, July 9.
Finally, Dr. Tamara Maes, Oryzon's Vice President and President of Oryzon's Scientific Advisory Board, and Dr. Robert Soliva, Oryzon's Head of Drug Discovery, will attend the Epigenetic Therapeutic Target Summit, which will be held July 14-15. Dr. Maes will provide a presentation entitled "Pharmaceutical R&D in Epigenetics at Oryzon Genomics" on July 14 at 11:00 CEST while Dr. Soliva will participate in a Panel Discussion entitled "HDAC3, BET, RNA, So Many Targets - Exploring New Potential in Well Known Targets to Create New Value & Diversify Pipelines" taking place on July 14 at 9:30 CEST.
About Oryzon
Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzon's LSD1 program has rendered two compounds, vafidemstat and iadademstat, in Phase II clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases. Oryzon has offices in Spain and the United States.
About Iadademstat
Iadademstat (ORY-1001) is a small oral molecule, which acts as a highly selective inhibitor of the epigenetic enzyme LSD1 and has a powerful differentiating effect in hematologic cancers (See Maes et al., Cancer Cell 2018 Mar 12; 33 (3): 495-511.e12.doi: 10.1016 / j.ccell.2018.02.002.). A first Phase I/IIa clinical trial with iadademstat in refractory and relapsed acute leukemia patients demonstrated the safety and good tolerability of the drug and preliminary sig...
(All Rights Reserved)